The world could always use more good news, and this week we’ve got some new discoveries to discuss. Up first, details on a trial that may have finally found a drug that can reduce the risk of death in severe COVID-19 cases. We also have information about positive results from a phase 1 trial for a therapy targeting the root cause of chronic urticarias, a disease that significantly impacts a patient’s quality of life. Finally, knowledge is always the best defense, and we’ve got a summary of a study that describes a new rare genetic disorder called TRAF7 syndrome. We hope you have a great weekend!
The finding may herald a major breakthrough in the treatment of the disease; treatment with just a small dose of the medication was able to reduce the risk of death significantly.
This disease can result in decreased energy, insomnia, social withdrawal, and even depression.
Some of the characteristics include distinctive facial features as well as skeletal abnormalities affecting the chest, fingers, and neck.